EI
DNTH icon

EFG International’s Dianthus Therapeutics DNTH Stock Holding History

EFG International’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$48.7K Hold
500
– – ﹤0.01% 784
2026
Q1 		$42K Hold
500
– – ﹤0.01% 744
2025
Q4 		$20.6K Buy
+500
New +$19.4K ﹤0.01% 764

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

EFG International's DNTH Position: Q2 2026 in Review

EFG International held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 500 shares worth $48.7K. The position accounts for ﹤0.01% of the portfolio, ranked #784.

EFG International first reported a position in DNTH in Q4 2025 and has held it in 3 quarters since. 270 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • EFG International held 500 shares of Dianthus Therapeutics worth $48.7K as of Q2 2026.
  • EFG International left its Dianthus Therapeutics share count unchanged in Q2 2026.
  • Dianthus Therapeutics made up ﹤0.01% of EFG International's portfolio in Q2 2026, its #784 holding.
  • EFG International first reported a position in Dianthus Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 270 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on EFG International's 13F filing for Q2 2026, filed 14 Aug 2026.